DUBLIN--(BUSINESS WIRE)--The "Global Respiratory Tract Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global respiratory tract infection treatment market was valued at US$ 34,276.8 Mn in 2016, and is expected to reach US$ 59,957.3 Mn by 2025 expanding at a CAGR of 6.2% from 2017 to 2025.
In base year 2016, the upper respiratory tract infection led the disease segment due to factors such as constant climate change and air pollution, gross negligence when it comes to personal hygiene like sneezing, coughing (uncovered face) and touching inanimate objects with contaminated hands.
Lower respiratory tract infection is anticipated to register faster growth in the disease segment throughout the forecast period 2017-2025, due to factors like rising number of air particulate matter, which causes respiratory tract irritation and infection and on the basis of transmission it might be hospital acquired, ventilator acquired, and community acquired.
In 2016, NSAIDs hold the largest market in the drug class segment due to factors such as low cost and easy availability as OTC products, technological advancement in the drug formulation e.g. ketorolac nasal spray to overcome NSAIDs adverse events.
The antibiotics will be the fastest growing market in the drug treatment segment throughout the forecast period 2017-2025, due to factors such as improved pharmacokinetics to specifically target the respiratory tract infection for e.g. Colistin inhalers.
Key Topics Covered
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global Respiratory Tract Infection Treatment Market Overview
Chapter 4 Global Respiratory Tract Infection Treatment Market, by Disease
Chapter 5 Global Respiratory Tract Infection Treatment Market, by Drug Class
Chapter 6 Global Respiratory Tract Infection Treatment Market, by Geography
Chapter 7 Company Profiles
- Abbott Laboratories
- Abbvie Inc.
- Boehringer Ingelheim GmbH
- Cipla Pharmaceutical Company
- GlaxoSmithkline plc
- Pfizer Inc.
- Merck & Co.
- Novartis AG
- F.Hoffman La Roche Ltd
- Teva Pharmaceutical Industries
For more information about this report visit https://www.researchandmarkets.com/research/vjp7cw/global?w=4